IASLC Thoracic Oncology , 2nd Edition

Description

Global experts, in conjunction with the International Association for the Study of Lung Cancer, bring you up to date with today’s best approaches to lung cancer diagnosis, treatment, and follow-up. IASLC Thoracic Oncology, 2nd Edition, keeps you abreast of the entire scope of this fast-changing field, from epidemiology to diagnosis to treatment to advocacy. Written in a straightforward, practical style for the busy clinician, this comprehensive, multidisciplinary title is a must-have for anyone involved in the care of patients with lung cancer and other thoracic malignancies.

Reviews

"Overall, this is an outstanding resource that everyone interested in this subject must have…. The main objective of this book and the well-thought-out content sets it apart from any other book in the same space." Reviewed by Ravi Salgia, MD, PhD (City of Hope) Doody's Score: 98, 5 Stars!

Key Features

• Offers practical, relevant coverage of basic science, epidemiology, pulmonology, medical and radiation oncology, surgery, pathology, palliative care, nursing, and advocacy.
• Provides authoritative guidance from the IASLC – the only global organization dedicated to the study of lung cancer.

New to this Edition

• Includes new content on molecular testing, immunotherapy, early detection, staging and the IASLC staging system, surgical resection for stage I and stage II lung cancer, and stem cells in lung cancer.
• Features a new full-color design throughout, as well as updated diagnostic algorithms.
• Expert Consult™ eBook version included with purchase. This enhanced eBook experience allows you to search all of the text, figures, Q&As, and references from the book on a variety of devices.

Companion Products

• IASLC Thoracic Oncology, 2nd Edition
• IASLC Thoracic Oncology E-Book, 2nd Edition : IASLC Thoracic Oncology E-Book

Table of Contents

• View Table of Contents

Author Information

By Harvey Pass, MD, Stephen E. Banner Professor of Thoracic Oncology, Vice Chair of Research NYUHC, Departments of Cardiothoracic Surgery, New York University Langone Medical Center, New York, New York; David Ball, MD, FRANZCR, Director, Lung Cancer Stream, Victorian Comprehensive Cancer Centre, Parkville Professional Fellow, the Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia and Giorgio Scagliotti, MD, PhD, Professor of Medical Oncology, Head of Department of Oncology at S. Luigi Hospital, University of Turin, Orbassano (Torino), Italy